Liproxstatin-1: Precision Ferroptosis Inhibition and Lipid Peroxidation Control

Executive Summary: Liproxstatin-1 (CAS 950455-15-9) is a potent, selective ferroptosis inhibitor with an IC50 of 22 nM for lipid peroxidation suppression in GPX4-deficient cells (Han et al., 2025). It blocks accumulation of lipid peroxides and protects against ferroptotic cell death (APExBIO). Liproxstatin-1 has demonstrated efficacy in animal models of kidney and hepatic injury. It is insoluble in water but soluble in DMSO (≥10.5 mg/mL) and ethanol (≥2.39 mg/mL) with gentle warming. The compound is essential for research into iron-dependent cell death and lipid peroxidation mechanisms.

Biological Rationale

Ferroptosis is a regulated form of cell death dependent on iron and characterized by the accumulation of lipid peroxides. Glutathione peroxidase 4 (GPX4) is the primary enzyme that detoxifies lipid peroxides in cells. Loss or inhibition of GPX4 leads to increased lipid peroxidation and triggers ferroptosis. Increased oxidative stress, as modeled in Sod1 knockout mice, correlates with elevated lipid peroxidation and ferroptosis in tissues (Han et al., 2025). Ferroptosis is implicated in pathological conditions such as acute kidney injury, hepatic ischemia/reperfusion injury, and neurodegeneration. Liproxstatin-1 enables precise dissection of the iron-dependent cell death pathway by selectively inhibiting lipid peroxidation (see detailed mechanism). This article builds on prior summaries by clarifying Liproxstatin-1's mechanistic selectivity and translational benchmarks.

Mechanism of Action of Liproxstatin-1

Liproxstatin-1 acts as a direct inhibitor of ferroptosis. It blocks the accumulation of lipid hydroperoxides generated during oxidative stress. The compound specifically prevents ferroptotic cell death induced by GPX4 inhibition or depletion. Liproxstatin-1 does not affect apoptosis or necroptosis pathways at relevant concentrations. Its protective effect is most pronounced in cellular models where GPX4 is genetically ablated or chemically inhibited (e.g., by RSL3). The molecular mechanism involves scavenging of lipid peroxyl radicals and inhibition of propagation of lipid peroxidation chain reactions (Han et al., 2025). For a workflow-oriented perspective, see this mechanistic analysis, which this article extends by providing direct product handling and benchmarking data.

Evidence & Benchmarks

• Liproxstatin-1 displays an IC50 of ~22 nM for inhibition of ferroptosis in GPX4-deficient cell lines (Han et al., 2025, DOI).
• It protects against lipid peroxidation triggered by RSL3 and other ferroptosis inducers in cultured cells (APExBIO, product page).
• In mouse models with conditional kidney-specific GPX4 deletion, Liproxstatin-1 treatment prolongs survival and reduces markers of tissue injury (Han et al., 2025, DOI).
• Administration of Liproxstatin-1 reduces damage in hepatic ischemia/reperfusion injury models (APExBIO, product page).
• It is insoluble in water, but soluble in DMSO (≥10.5 mg/mL) and ethanol (≥2.39 mg/mL) when gently warmed or sonicated (APExBIO, specification).
• Short-term stability of Liproxstatin-1 in solution is optimal at -20°C (APExBIO, specification).
• In SOD1 knockout mouse models of oxidative stress, ferroptosis markers are elevated and are ameliorated by ferroptosis inhibition (Han et al., 2025, DOI).

Applications, Limits & Misconceptions

Liproxstatin-1 is used to dissect ferroptosis mechanisms in cell and tissue models. It is a research tool for studying iron-dependent cell death in GPX4-deficient systems, renal and hepatic injury, and lipid peroxidation pathways. Its efficacy in vivo has been validated in mouse models. However, Liproxstatin-1 is not effective in blocking cell death forms unrelated to lipid peroxidation or iron metabolism. For in-depth translational strategies, see this review, which this article updates by specifying Liproxstatin-1's solubility, selectivity, and validated use cases.

Common Pitfalls or Misconceptions

• Liproxstatin-1 does not inhibit apoptosis, necroptosis, or other non-ferroptotic pathways at standard research doses.
• Solubility in water is negligible; always dissolve in DMSO or ethanol with warming/sonication.
• Long-term storage of Liproxstatin-1 solutions at room temperature leads to rapid degradation; store at -20°C for short term only.
• Protective effects are context-specific; Liproxstatin-1 is not a universal antioxidant.
• Translational or clinical applications remain investigational; Liproxstatin-1 is strictly for research use.

Workflow Integration & Parameters

Liproxstatin-1 (SKU B4987) from APExBIO is supplied as a solid. For experimental use, dissolve at concentrations ≥10.5 mg/mL in DMSO or ≥2.39 mg/mL in ethanol, applying gentle warming or ultrasonic treatment. Use freshly prepared solutions; avoid repeated freeze-thaw cycles. For cellular assays, titrate concentrations to span 1–100 nM for optimal selectivity. For animal studies, dose according to established protocols and adjust for solubility carrier and route of administration. Detailed experimental workflow guidance can be found in this strategic article, which this article complements by providing benchmarking and handling recommendations specific to APExBIO's Liproxstatin-1.

Conclusion & Outlook

Liproxstatin-1 is a leading tool compound for ferroptosis research, enabling targeted inhibition of lipid peroxidation in GPX4-deficient and injury models. Its nanomolar potency and selectivity set a benchmark for iron-dependent cell death pathway research. While not a broad-spectrum cytoprotectant, Liproxstatin-1 remains essential for dissecting the molecular underpinnings of ferroptosis and lipid peroxidation. For detailed product specifications and ordering, visit the Liproxstatin-1 product page by APExBIO.